Download Curriculum Vitae

Dr. Strand completed his PhD in the laboratory of David Rowley, PhD in the department of Molecular and Cellular Biology at Baylor College of Medicine. There he worked on the molecular mechanisms regulating reactive stroma in prostate cancer. From there Dr. Strand moved on to the laboratory of Simon Hayward, PhD in the Urology department at Vanderbilt University to perform his post-doctoral training. It was here that Dr. Strand developed an interest in solving the cellular and molecular pathogenesis of benign prostatic hyperplasia. In 2014, Dr. Strand joined forces with Claus Roehrborn, MD, chair of the Urology department at UT Southwestern and a world-renowned expert in BPH treatment. Dr. Strand has developed an unparalleled human tissue biorepository that is used for his translational research program and is actively pursuing molecular targets for the development of novel medical treatments for this widespread disease.


Liberty University (2001), Biology
Graduate School
Baylor College of Medicine (2007), Molecular & Cell Biology

Research Interest

  • Benign Prostatic Hyperplasia
  • Prostate Cancer


Featured Publications LegendFeatured Publications

The many ways to make a luminal cell and a prostate cancer cell.
Strand DW, Goldstein AS Endocr. Relat. Cancer 2015 Aug
SOX2 expression in the developing, adult, as well as, diseased prostate.
Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ Prostate Cancer Prostatic Dis. 2014 Aug
FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype.
DeGraff DJ, Grabowska MM, Case TC, Yu X, Herrick MK, Hayward WJ, Strand DW, Cates JM, Hayward SW, Gao N, Walter MA, Buttyan R, Yi Y, Kaestner KH, Matusik RJ Lab. Invest. 2014 Jul 94 7 726-39
TGF-ß induction of FGF-2 expression in stromal cells requires integrated smad3 and MAPK pathways.
Strand DW, Liang YY, Yang F, Barron DA, Ressler SJ, Schauer IG, Feng XH, Rowley DR Am J Clin Exp Urol 2014 2 3 239-48
SPARCL1 suppresses metastasis in prostate cancer.
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, He X, Jin X, Hayward SW, Matusik RJ, George AL, Yi Y Mol Oncol 2013 Dec 7 6 1019-30

Honors & Awards

  • AUA Travel Award
  • K01DK098277
    Mentored training grant on the role of metabolism in prostate differentiation and disease (2013-2018)
  • StarBrite VICTR award
    Pilot funding to study the role of inflammation in BPH progression (2013-2014)
  • SBUR Travel award and podium presentation
  • NIH LRP award
    Loan repayment program award (2010-2012)
  • StarBrite VICTR award
    Pilot funding to study the role of lipid metabolism in prostate cancer (2010-2011)
  • DoD Postdoctoral Training Award
    2 year fellowship to study the role of stomal-epithelial interactions in prostate cancer progression (2009-2011)
  • SBUR travel award

Professional Associations/Affiliations

  • American Urological Association (2014)
  • Society for Basic Urologic Research (2009)